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METHODS: A total of 361 patients with AF (mean age 71 ± 9,
61% male) in 45 physician practices throughout Germany were
recruited. 3-month retrospective and 6-month prospective clini-
cal data including INR values and anticoagulation strategy were
obtained from the physician chart through standardised ques-
tionnaire. Patient health-related and disease-speciﬁc quality of
life was assessed with the SF-36 and MacNew heart disease
instruments. The patient completed a standardised questionnaire
at three and six months, which documented hospitalisations,
medications, and complications, as well as quality of life, patient
satisfaction and compliance. Three hundred-four (84%) patients
completed the entire study. RESULTS: Of all patients, 90% had
been treated with VKAs at some time since AF-diagnosis, 88%
were still on treatment. 10% of the patients received aspirin as
their anticoagulation therapy. INR was measured at least once a
month in over 70% of the patients. INR values were 56% of the
time within, 14% below and 30% over the target range. SF-36
results were similar to patients of comparable age and health.
Fifty-ﬁve percent of patients reported they were always or mostly
satisﬁed with their treatment and 66% stated they complied with
their prescribed treatment most or all of the time. CONCLU-
SIONS: This study presents German “real-life” data in treating
patients with AF and identiﬁes the potential to advance the
quality of care particularly with respect to anticoagulation.
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OBJECTIVE: Rational administration of drugs takes into
account drug price/type,pharmaceutical form, unit dose price,
associating success of a treatment with a given drug or drugs
with expenses related to the speciﬁc therapy. The paper is aimed
at: analysis of antihypertensive therapy prescription practice
along with economic parameters and analysis of consumption of
antihypertensive drugs in the Clinical Center of Serbia (CCS) in
accordance with the National Guide to Prevention of Ischemic
Disease. In spite of the high distribution of other heart diseases
in the structure of cardiovascular deaths, Serbia is, based on the
WHO data, classiﬁed into the group of countries with relatively
high risk of deaths associated with coronary diseases, among
both males and females aged between 40 and 49 years.
METHODS: The study was carried out at the CCS based on the
data provided by the Pharmacy and Medical Supply. All the
drugs mentioned in the analyses are registered in Serbia and 
the costs of the consumed drugs are reimbursed (100%) by the
Republic Health Insurance Fund. The analysis includes con-
sumption of drugs (according to groups) intended for treatment
of hypertension in CCS over the six-month period. Consump-
tion-based method is used as a quantiﬁcation method. RESULTS:
The patients were administered either single or combined drug
antihypertensive therapy. All groups of the studied drugs were
proved to lower arterial blood pressure, reduce morbidity and
mortality associated with the cardiovascular and cerebrovascu-
lar diseases, which was the basic aim of the applied therapy.
Diuretics and beta-blockers are most common drugs in treatment
of hypertension and their efﬁcacy and safety are best docu-
mented. CONCLUSION: Serbia needs restructuring of the
health care system and introduction of non-budgetary ﬁnancing,
adequate validation of health care services, privatization of
public sector and new legal regulations corresponding to the
changed economic environment.
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OBJECTIVE: The aim of this study was to review randomized
controlled trials (RCTs) comparing Valsartan 20/40/80 mg,
Telmisartan 80/160 mg, Losartan 50/100 mg and Irbesartan
75/150 mg at starting doses. A literature review of ARBs has not
been previously performed. METHODS: Published literature
was reviewed using OVID Medline, Embase, PubMed and
Cochrane databases, cut-off date June 8th, 2006, as sources of
data and the abstracted data were recorded into structured
forms. The quality of selected studies was assessed by CRD
Report No 4, University of York. Search terms included “mild
hypertension”, “moderate hypertension”, “anti-hypertensive
agents” and others combined with the speciﬁc drug terms.
Studies included were either “head-to-head” trials or random-
ized, double-blind or open label placebo-controlled trials
(RCTs). Clinical measurement of blood pressure included not
only ambulatory blood pressure monitoring (ABPM), but cuff
BP and sphygmomanometer also. Patient population was deﬁned
as mild-to-moderate hypertension with no concomitant diseases.
RESULTS: Forty-seven studies were included in the analysis.
Duration of treatment was typically 8 to 12 weeks. Sample size
ranged between 25 and 14820 patients. Mean age of sample
ranged between 47 and 63 years. Of the selected literature, 29
studies were head-to-head trials, 20 were RCTs versus placebo
and 8 were dose-response trials of the regimen. With respect to
BP measurements, 14 studies used ABPM in contrast to 25 that
used clinic BP. The remaining 8 reported both. With respect to
study design 3 studies were meta-analyses, 25 were double-blind
RCTs, 1 was a single-blind single-arm trial and 11 were open-
label studies. 11 studies included either forced or elective titra-
tion. Finally, from the sample, irbesartan had the less retrieval,
given that it is the newer agent of all. CONCLUSION: All studies
complied with the CRD Report No 4 quality assessment crite-
ria, University of York. The literature review was performed to
be used for meta-analytic purposes.
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OBJECTIVES: Analysis of cost-effectiveness in clinical trials
often employs the incremental cost-effectiveness ratio (ICER) as
an index of cost-effectiveness. Because the index is a ratio of cost
differences divided by effect differences, and non-normally dis-
tributed, bootstrap methods are often used to assess its distrib-
ution. Conﬁdence intervals are potentially ambiguous because
ICERs with the same sign can have different interpretations
depending on their location in the cost-effectiveness plane. The
objective of this study was to use random permutation methods
in conjunction with the bootstrap to assess whether the cost and
effectiveness distribution differs from what would be expected
by chance. METHODS: Assuming treatment effectiveness, cost
data are simulated that follow normal, gamma and triangular
distributions. Bootstrap methods are employed to estimate the
cost and effectiveness distribution. The data are then randomly
permuted and the distribution compared with the bootstrap 
distribution. RESULTS: Random permutations for all simulated
cost distributions indicated an expected proportion of 0.25 
of cost and effectiveness pairs in each quadrant of the cost-
